Bifogade filer
Kurs & Likviditet
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
STOCKHOLM, SWEDEN - 9 May 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the first quarter 2023. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.
John Öhd, Modus Therapeutics' CEO, commented: ” In Q1 we announced 3 key achievements that give us great confidence in our ability to make further important progress in 2023. These were:
• Positive topline data from our Phase 1b lipopolysaccharide (LPS) provocation study.
• Submitting a patent application based on new data for the use of sevuparin, in kidney disease and anemia, a significant new market opportunity.
• Securing access to bridge financing of up to SEK 7.0 million from our largest shareholder, Karolinska Development.
I am looking forward to an exciting 2023 as the enhanced communication of our science and data will further highlight the potential of sevuparin to all of our key stakeholders and potential partners.”
The first quarter in figures
- The loss after tax amounted to TSEK 6 040 (3 065).
- The loss per share amounted to SEK 0,38 (0,19).
- The cash flow from current operations was negative in the amount of TSEK 6 335 (7 545).
Important events during the first quarter
- Modus Therapeutics submits patent application for sevuparin in kidney disease.
- Modus Therapeutics announces positive topline data from its Phase 1b LPS provocation study evaluating the potential of sevuparin for treatment of sepsis.
- Modus Therapeutics participated in BIO-Europe spring, Basel.
- Modus Therapeutics secures access to bridge financing (subject of approval at the AGM 11 May, 2023).
Important events after the end of the period
- Modus Therapeutics participated in LSX, London.
CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid today May 9th at 13:30 Link to Interview: https://www.youtube.com/live/Bno5mi8dRwU?feature=share